Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLD NASDAQ:HALO NASDAQ:IONS NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$6.06-3.5%$6.08$5.51▼$12.65$1.93B0.514.10 million shs3.51 million shsHALOHalozyme Therapeutics$58.24-0.9%$54.76$42.01▼$70.50$7.24B1.152.42 million shs1.10 million shsIONSIonis Pharmaceuticals$42.24+0.2%$38.20$23.95▼$52.34$6.71B0.231.81 million shs887,852 shsRGENRepligen$121.74-0.1%$123.58$102.96▼$182.52$6.85B1.11754,837 shs950,629 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics-3.50%+1.68%+7.07%-17.55%-41.45%HALOHalozyme Therapeutics-0.90%+3.17%+11.31%-3.72%+5.60%IONSIonis Pharmaceuticals+0.21%+1.15%+5.60%+42.22%-16.75%RGENRepligen-0.11%+4.72%-1.84%-15.90%-7.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFOLDAmicus Therapeutics4.0568 of 5 stars3.41.00.04.32.70.01.9HALOHalozyme Therapeutics4.8524 of 5 stars2.14.00.04.42.92.54.4IONSIonis Pharmaceuticals4.5355 of 5 stars4.32.00.03.02.73.30.6RGENRepligen4.6397 of 5 stars4.31.00.04.52.21.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.80Moderate Buy$16.22167.69% UpsideHALOHalozyme Therapeutics 2.17Hold$62.707.66% UpsideIONSIonis Pharmaceuticals 2.62Moderate Buy$55.6731.79% UpsideRGENRepligen 2.69Moderate Buy$169.9239.57% UpsideCurrent Analyst Ratings BreakdownLatest FOLD, HALO, IONS, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025RGENRepligenStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight$160.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight7/16/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$58.00 ➝ $60.007/10/2025HALOHalozyme TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$55.007/8/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/24/2025RGENRepligenBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$150.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$528.29M3.53N/AN/A$0.65 per share9.32HALOHalozyme Therapeutics$1.02B7.07$4.61 per share12.63$2.86 per share20.36IONSIonis Pharmaceuticals$705M9.54N/AN/A$3.73 per share11.32RGENRepligen$634.44M10.78$3.10 per share39.23$35.21 per share3.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$56.11M-$0.09N/A14.09N/A-5.41%4.67%1.05%7/31/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7615.499.360.3944.76%136.91%26.05%8/5/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)RGENRepligen-$25.51M-$0.45N/A51.582.27-3.93%4.53%3.17%7/29/2025 (Estimated)Latest FOLD, HALO, IONS, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HALOHalozyme Therapeutics$1.22N/AN/AN/A$282.66 millionN/A7/31/2025Q2 2025FOLDAmicus Therapeutics$0.01N/AN/AN/A$146.68 millionN/A7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19N/AN/AN/A$270.90 millionN/A7/29/2025Q2 2025RGENRepligen$0.40N/AN/AN/A$174.62 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics2.023.342.47HALOHalozyme Therapeutics3.138.397.30IONSIonis Pharmaceuticals2.639.669.62RGENRepligen0.276.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AHALOHalozyme Therapeutics97.79%IONSIonis Pharmaceuticals93.86%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%HALOHalozyme Therapeutics2.40%IONSIonis Pharmaceuticals2.60%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableFOLD, HALO, IONS, and RGEN HeadlinesRecent News About These Companies16,436 Shares in Repligen Corporation (NASDAQ:RGEN) Bought by Neo Ivy Capital ManagementJuly 26 at 6:58 AM | marketbeat.comCrestwood Advisors Group LLC Makes New $464,000 Investment in Repligen Corporation (NASDAQ:RGEN)July 24 at 4:41 AM | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Stock Position Boosted by Legato Capital Management LLCJuly 23 at 7:15 AM | marketbeat.comRepligen (RGEN) Receives Overweight Rating with $160 Price Target | RGEN Stock NewsJuly 22, 2025 | gurufocus.comRepligen (NASDAQ:RGEN) Coverage Initiated by Analysts at StephensJuly 22, 2025 | marketbeat.comRepligen (RGEN) Projected to Post Quarterly Earnings on TuesdayJuly 22, 2025 | marketbeat.comLeerink Partnrs Expects Increased Earnings for RepligenJuly 22, 2025 | americanbankingnews.comHere's Why Repligen (RGEN) is a Strong Growth StockJuly 21, 2025 | zacks.comRepligen FY2025 EPS Forecast Increased by Leerink PartnrsJuly 21, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for Repligen Q1 Earnings?July 20, 2025 | americanbankingnews.comWinners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services StocksJuly 18, 2025 | msn.com3 Reasons RGEN is Risky and 1 Stock to Buy InsteadJuly 18, 2025 | msn.comRepligen Corp (RGEN) Trading Down 4.19% on Jul 18July 18, 2025 | gurufocus.comQ1 Earnings Estimate for Repligen Issued By Leerink PartnrsJuly 18, 2025 | marketbeat.comRepligen to Report Second Quarter 2025 Financial ResultsJuly 17, 2025 | globenewswire.comSegall Bryant & Hamill LLC Grows Stake in Repligen Corporation (NASDAQ:RGEN)July 17, 2025 | marketbeat.comRepligen Corporation (NASDAQ:RGEN) Shares Acquired by Rice Hall James & Associates LLCJuly 15, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Trading Down 5.4% - Here's WhyJuly 14, 2025 | marketbeat.comTimesSquare Capital Management LLC Has $30.03 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comSlow Capital Inc. Has $4.18 Million Stock Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comNew York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)July 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings Season2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsFOLD, HALO, IONS, and RGEN Company DescriptionsAmicus Therapeutics NASDAQ:FOLD$6.06 -0.22 (-3.50%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.09 +0.03 (+0.50%) As of 07/25/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Halozyme Therapeutics NASDAQ:HALO$58.24 -0.53 (-0.90%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$58.25 +0.01 (+0.02%) As of 07/25/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Ionis Pharmaceuticals NASDAQ:IONS$42.24 +0.09 (+0.21%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$42.23 -0.01 (-0.02%) As of 07/25/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Repligen NASDAQ:RGEN$121.74 -0.13 (-0.11%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$123.33 +1.59 (+1.31%) As of 07/25/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
